







## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : C07D 241/08, 261/08, 263/10, 405/06, 261/04, 263/32, 413/12, 417/12, 277/30, 417/04, A61K 31/42, 31/415, 31/495, C07D 231/06, 231/12</p>	A1	<p>(11) International Publication Number: <b>WO 00/00477</b></p> <p>(43) International Publication Date: 6 January 2000 (06.01.00)</p>
<p>(21) International Application Number: PCT/IB99/00973</p> <p>(22) International Filing Date: 31 May 1999 (31.05.99)</p> <p>(30) Priority Data: 60/091,180 30 June 1998 (30.06.98) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DUPLANTIER, Allen, Jacob [US/US]; 431 Pumpkin Hill Road, Ledyard, CT 06339 (US). MILICI, Anthony, John [US/US]; 17 Chapel Drive, Branford, CT 06405 (US). CHUPAK, Louis, Stanley [US/US]; 4 Stone Boat Road, Old Saybrook, CT 06475 (US).</p> <p>(74) Agents: SPIEGEL, Allen, J.; Simpson, Alison, Urquhart-Dykes &amp; Lord, 91 Wimpole Street, London W1M 8AH (GB) et al.</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p>
<p>(54) Title: NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES</p>		
<div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>(1.0.0)</p> </div> <div style="text-align: center;">  <p>(1.1.2)</p> </div> <div style="text-align: center;">  <p>(1.1.6)</p> </div> <div style="text-align: center;">  <p>(1.9.0)</p> </div> </div>		
<p>(57) Abstract</p> <p>Compounds of Formula (1.0.0) are described, wherein A is for example aryl, heteroaryl or heterocyclyl, Y is preferably -C(=O)-; B is independently selected from a group of moieties, the most preferred of which are those of partial Formulas (1.1.2) and (1.1.6), and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH<sub>3</sub>)<sub>2</sub>; CF<sub>2</sub>; or a bridging moiety of partial Formula (1.9.0), where R<sub>1a</sub> is hydrogen when R<sup>1</sup> has the meaning of a mono-valent substituent; and R<sub>1a</sub> is a single bond when R<sup>1</sup> has the meaning of a di-valent substituent. Said compounds are useful in methods of treating or preventing an inflammatory, autoimmune or respiratory disease by inhibiting cell adhesion and consequent or associated pathogenic processes subsequently mediated by VLA-4.</p>		